Please use this identifier to cite or link to this item:
http://hdl.handle.net/2445/107169
Title: | Inherited functional variants of the lymphocyte receptor CD5 influence melanoma survival |
Author: | Potrony Mateu, Míriam Carreras Margalef, Esther Aranda, Fernando Zimmer, Lisa Puig Butillé, Joan Anton Tell Martí, Gemma Armiger Borràs, Noelia Sucker, Antje Gimenez-Xavier, Pol Martínez-Florensa, Mario Carrera Álvarez, Cristina Malvehy, J. (Josep) Schadendorf, Dirk Puig i Sardà, Susana Lozano Soto, Francisco |
Keywords: | Melanoma Receptors cel·lulars Oncologia Melanoma Cell receptors Oncology |
Issue Date: | 15-Sep-2016 |
Publisher: | Wiley |
Abstract: | Despite the recent progress in treatment options, malignant melanoma remains a deadly disease. Besides therapy, inherited factors might modulate clinical outcome, explaining in part widely varying survival rates. T-cell effector function regulators on antitumor immune responses could also influence survival. CD5, a T-cell receptor inhibitory molecule, contributes to the modulation of antimelanoma immune responses as deduced from genetically modified mouse models. The CD5 SNPs rs2241002 (NM_014207.3:c.671C > T, p.Pro224Leu) and rs2229177 (NM_014207.3:c.1412C > T, p.Ala471Val) constitute an ancestral haplotype (Pro224-Ala471) that confers T-cell hyper-responsiveness and worsens clinical autoimmune outcome. The assessment of these SNPs on survival impact from two melanoma patient cohorts (Barcelona, N = 493 and Essen, N = 215) reveals that p.Ala471 correlates with a better outcome (OR= 0.57, 95% CI = 0.33-0.99, Adj. p = 0.043, in Barcelona OR = 0.63, 95% CI = 0.40-1.01, Adj. p = 0.051, in Essen). While, p.Leu224 was associated with increased melanoma-associated mortality in both cohorts (OR = 1.87, 95% CI = 1.07-3.24, Adj. p = 0.030 in Barcelona and OR = 1.84, 95% CI = 1.04-3.26, Adj. p = 0.037, in Essen). Furthermore survival analyses showed that the Pro224-Ala471 haplotype in homozygosis improved melanoma survival in the entire set of patients (HR = 0.27, 95% CI 0.11-0.67, Adj. p = 0.005). These findings highlight the relevance of genetic variability in immune-related genes for clinical outcome in melanoma. |
Note: | Versió postprint del document publicat a: https://doi.org/10.1002/ijc.30184 |
It is part of: | International Journal of Cancer, 2016, vol. 139, num. 6, p. 1297-1302 |
URI: | http://hdl.handle.net/2445/107169 |
Related resource: | https://doi.org/10.1002/ijc.30184 |
ISSN: | 0020-7136 |
Appears in Collections: | Articles publicats en revistes (Medicina) Articles publicats en revistes (Biomedicina) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
667669.pdf | 219.34 kB | Adobe PDF | View/Open |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.